Jump to navigation Jump to search
|Chemical and physical data|
|Molar mass||144.1 kDa|
Galcanezumab, marketed under the trade name Emgality, is a humanized monoclonal antibody used for the prevention of migraine. It is directed against calcitonin-related polypeptides alpha and beta.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Galcanezumab, American Medical Association.
- World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- H. Spreitzer (3 July 2017). "Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab". Österreichische Apothekerzeitung (in German) (14/2017).
- "US FDA approves Lilly migraine drug at a price that is the same as its rivals". CNBC. Reuters. 28 September 2018. Retrieved 29 September 2018.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|